Lars Egevad's Group

Denna sida på svenska

The primary target of our group is urological tumors, particularly prostate cancer and renal cell carcinoma.

Prostate cancer is the most common type of cancer and the most frequent cause of death from cancer in Swedish men. A main problem with its treatment is the lack of informative biomarkers for diagnosis and prognosis, leading to high levels of overtreatment. There is an evident need of improved methods for stratification of the patients into clinically relevant prognostic groups.

Renal cancer is particularly prevalent in some parts of the EU and associated with relatively poor prognosis. The underlying cause of renal cancer is not clear although some risk factors are known such as smoking, heredity and obesity. The high incidence in eastern Europe is not entirely explained by the high prevalence of smoking. There is a need of improved methods for treating disseminated disease as well as adjuvant treatment of high-stage, high-risk tumors.

The search for biomarkers is conducted on gene level by sequencing for molecular signatures and on protein level by using immunohistochemistry on tissue microarrays.

Our group is part of a couple of large research consortiums:

  • the CRisP group supported by a Linné grant from the Swedish Research council (breast and prostate cancer)
  • the CAGEKID group supported by an FP7 grant from EU (renal cell carcinoma). The CAGEKID project is listed as an ICGC (International Cancer Genome Consortium) project

We are also involved in international standardization of histopathological assessment of urological tumors. International consensus meetings are regularly organized through the International Society of Urological Pathology (ISUP) and by coordinating the European Network of Urological Pathology (ENUP) we attempt to standardize how urological pathology is applied in practice in Europe.

Group members

Lars Egevad, MD, PhD, Professor, Group leader
Daniela Danneman, MD, PhD student
Anna Kristiansen, MD, PhD student
Claes Lindh, MD, PhD student
Jóna Guðjónsdóttir, Laboratory technician

Selected publications

Differential protein expression in anatomical zones of the prostate.
Lexander H, Franzén B, Hirschberg D, Becker S, Hellström M, Bergman T, et al
Proteomics 2005 Jul;5(10):2570-6

Proteomic analysis of protein expression in prostate cancer.
Lexander H, Palmberg C, Auer G, Hellström M, Franzén B, Jörnvall H, et al
Anal. Quant. Cytol. Histol. 2005 Oct;27(5):263-72

Evaluation of two sample preparation methods for prostate proteome analysis.
Lexander H, Hellman U, Palmberg C, Auer G, Hellström M, Franzén B, et al
Proteomics 2006 Jul;6(13):3918-25

Correlation of protein expression, Gleason score and DNA ploidy in prostate cancer.
Lexander H, Palmberg C, Hellman U, Auer G, Hellström M, Franzén B, et al
Proteomics 2006 Aug;6(15):4370-80

Expression of PDX-1 in prostate cancer, prostatic intraepithelial neoplasia and benign prostatic tissue.
Jonmarker S, Glaessgen A, Culp W, Pisa P, Lewensohn R, Ekman P, et al
APMIS 2008 Jun;116(6):491-8

Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer.
Glaessgen A, Jonmarker S, Lindberg A, Nilsson B, Lewensohn R, Ekman P, et al
APMIS 2008 Oct;116(10):888-95

Intra- and interobserver reproducibility of interpretation of immunohistochemical stains of prostate cancer.
Jaraj S, Camparo P, Boyle H, Germain F, Nilsson B, Petersson F, et al
Virchows Arch. 2009 Oct;455(4):375-81

GAD1 is a biomarker for benign and malignant prostatic tissue.
Jaraj S, Augsten M, Häggarth L, Wester K, Pontén F, Ostman A, et al
Scand. J. Urol. Nephrol. 2011 Feb;45(1):39-45

Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins.
Lindberg J, Klevebring D, Liu W, Neiman M, Xu J, Wiklund P, et al
Eur. Urol. 2013 Feb;63(2):347-53

Standardization of Gleason grading among 337 European pathologists.
Egevad L, Ahmad A, Algaba F, Berney D, Boccon-Gibod L, Compérat E, et al
Histopathology 2013 Jan;62(2):247-56

Full list of publications July 2013